Melamed M R
Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
J Occup Med. 1990 Sep;32(9):829-33. doi: 10.1097/00043764-199009000-00014.
The diagnosis and classification of bladder cancer are based primarily on histologic and cytologic light microscopy. The significant cytologic alternations are abnormal (increased) DNA content and structural changes in chromatin. Measurements of DNA content carried out by flow cytometry on suspensions of tumor cells and bladder irrigation specimens correlate well with clinical and biopsy findings. Badalament et al (Badalament RA, Kimmel M, Gay H, et al. Cancer 1987;59:2078-2085) reported that a single bladder wash flow cytometry correctly detected 83% of bladder cancers. The technique is most sensitive in detecting early, in situ, and superficially invasive carcinoma. In 100 urologic patients with non-neoplastic disease of the bladder, Klein et al (Klein FA, Herr HW, Sogani PC, et al. J Urol. 1982;127:946-948) reported only two false-positive examinations. Flow cytometry appears to be at least as valuable as conventional urinary cytology, without the need of an experienced cytopathologist. However, as specimens must be collected by bladder irrigation via catheter or cytoscope, the technique is most suitable not for population screening, but in monitoring high-risk populations: industrial workers or others exposed to carcinogens, persons with a history of urothelial tumors, and adult patients referred for urologic examinations because of hematuria, unexplained, recurrent cystitis, or other urologic symptoms. DNA flow cytometry also has been valuable in monitoring the conservative treatment of bladder cancer and of predictive value in the intravesical bacille Calmette-Guérin treatment of superficial carcinomas of the bladder. Dual parameter measurements of DNA content and antigen expression are now under evaluation, as are measurements of chromatin structure alteration, metabolism, and proliferative rate. These promise to discriminate subsets of bladder cancer that may be predictive of clinical behavior.
膀胱癌的诊断和分类主要基于组织学和细胞学的光学显微镜检查。显著的细胞学改变是DNA含量异常(增加)和染色质结构变化。通过流式细胞术对肿瘤细胞悬液和膀胱冲洗标本进行的DNA含量测量与临床和活检结果密切相关。巴达勒门特等人(Badalament RA、Kimmel M、Gay H等。Cancer 1987;59:2078 - 2085)报告称,单次膀胱冲洗流式细胞术能正确检测出83%的膀胱癌。该技术在检测早期、原位和浅表浸润性癌方面最为敏感。在100例患有膀胱非肿瘤性疾病的泌尿外科患者中,克莱因等人(Klein FA、Herr HW、Sogani PC等。J Urol. 1982;127:946 - 948)报告仅有两次假阳性检查。流式细胞术似乎至少与传统尿液细胞学一样有价值,且无需经验丰富的细胞病理学家。然而,由于标本必须通过导管或膀胱镜进行膀胱冲洗采集,该技术最适合的不是人群筛查,而是监测高危人群:产业工人或其他接触致癌物的人、有尿路上皮肿瘤病史的人,以及因血尿、不明原因的复发性膀胱炎或其他泌尿系统症状而转诊进行泌尿外科检查的成年患者。DNA流式细胞术在监测膀胱癌的保守治疗以及对膀胱浅表癌的卡介苗膀胱内治疗的预测价值方面也很有价值。目前正在评估DNA含量和抗原表达的双参数测量,以及染色质结构改变、代谢和增殖率的测量。这些有望区分可能预测临床行为的膀胱癌亚组。